% of patients with ischemic stroke treated |
28.30% |
20.94% |
% of all patients with stroke treated |
24.62% |
18.22% |
% of all patients with stroke who receive CTP |
0.00% |
49.42% |
Favorable outcome (mRS, 0.1) |
39.44% |
40.03% |
mRS outcomes for patients with ischemic stroke |
|
|
% with 90-day mRS 0 |
18.41% |
18.23% |
% with 90-day mRS 1 |
21.03% |
21.80% |
% with 90-day mRS 2 |
12.56% |
11.96% |
% with 90-day mRS 3 |
13.14% |
13.27% |
% with 90-day mRS 4 |
15.75% |
16.13% |
% with 90-day mRS 5 |
7.13% |
6.78% |
% dead at 90 days |
11.98% |
11.83% |
Life-years |
0.2115 |
0.2119 |
QALYs |
0.1241 |
0.1246 |
Hospitalization costs (including SICH) (in US $) |
$11,400 |
$11,358 |
Novel diagnostic costs (in US $) |
$0 |
$236 |
Drug costs (in US $) |
$1,070 |
$792 |
Total costs (in US $) |
$12,470 |
$12,386 |
Incremental cost per life-year gained (in US $) |
– |
Cost-saving |
Incremental cost per QALY gained (in US $) |
– |
Cost-saving |
Incremental cost per major disability avoided (mRS, ≥3) (in US $) |
|
Cost-saving |